Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
Aptose Tuspetinib Data Featured in Oral Presentation
Dr. Naval Daver from MD Anderson Cancer Center will present data from Aptose™s AML Drug Candidate Tuspetinib in an Oral Presentation at ASH 2023
Aptose Presents Latest Available Data on AML Drug Tuspetinib - 48% ORR with TUS/VEN in Heavily Pre-treated R/R AML Patients
Aptose to Hold Clinical Update Webcast and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th